Table 1 Characteristics of the study population
Variables | Total (n = 175) | Non-survivors (n = 31) | Survivors (n = 144) | p-value |
|---|---|---|---|---|
Gender (male/female) | 146/29 | 27/4 | 119/25 | 0.545 |
Age (y) Mean ± SD | 48.6 ± 12.3(24–87) | 53.8 ± 13.6(31–79) | 47.5 ± 11.8(24–87) | 0.009* |
Etiology of liver disease n (%) | 0.087 | |||
Hepatitis B virus | 124(64.9) | 16(45.7) | 108(69.2) | |
Hepatitis C virus | 5(2.6) | 2(5.7) | 3(1.9) | |
Hepatitis E virus | 4(2.1) | 2(5.7) | 2(1.3) | |
Alcoholic liver disease | 35(18.3) | 10(28.6) | 25(16) | |
Primary biliary cirrhosis | 4(2.1) | 1(2.9) | 3(1.9) | |
Autoimmune hepatitis | 5(2.6) | 1(2.9) | 4(2.6) | |
Nonalcoholic steatohepatitis | 5(2.6) | 1(2.9) | 4(2.6) | |
Drug-induced hepatitis | 9(4.7) | 2(5.7) | 7(4.5) | |
Liver disease stage | 0.469 | |||
CLD | 44(25.1) | 5(16.1) | 39(27.1) | |
compensated cirrhosis | 24(13.7) | 5(16.1) | 19(13.2) | |
decompensated cirrhosis | 107(61.1) | 21(67.7) | 86(59.7) | |
Biocharacteristics | ||||
Albumin(g/L) | 31.3 ± 6.3(17.1–69.4) | 30.1 ± 8.8(17.1–69.4) | 31.5 ± 5.6(19.7–66.5) | 0.315 |
Creatinine(µmol/L) | 71.2(59.1–84.3) | 78.6(58.4-127.4) | 70.0(59.1–81.8) | 0.049* |
Total bilirubin(µmol/L) | 250.6 ± 125.0(87.3-614.3) | 303.3 ± 149.6(96.7-614.3) | 240.3 ± 120.3(87.3-553.4) | 0.016* |
INR | 2.3 ± 0.6(1.5–5.4) | 2.5 ± 0.9(1.6–5.4) | 2.3 ± 0.6(1.5–4.5) | 0.091 |
ALT(U/L) | 230.7(65.2-752.8) | 29.2(72.9-335.3) | 288.9(85.8-813.4) | 0.001* |
AST(U/L) | 231.5(108.2-641.2) | 116.1(81.2-310.8) | 251.8(125.1-670.6) | 0.094 |
WBC (×109/L) | 6.3(4.3–8.5) | 7.5(4.3–13.5) | 6.5(4.4–8.1) | 0.100 |
Monocyte (×109/L) | 0.6(0.4–0.8) | 0.7(0.4-1.0) | 0.6(0.4–0.8) | 0.069 |
CRP(mg/L) | 12.2(6.9–21.1) | 26.1(12.3–51.0) | 10.7(6.6–17.3) | <0.001* |
HE | 50(28.6) | 20(64.5) | 30(20.8) | <0.001* |
CTP class | 0.526 | |||
CTP B | 1(3.1) | 27(18.8) | 28(16.0) | |
CTP C | 30(96.8) | 117(81.3) | 147(84.0) | |
MELD score | 23.5 ± 5.0(14.2–39.8) | 27.5 ± 5.8(16.9–39.8) | 22.9 ± 4.4(14.2–35.8) | <0.001* |